Merck Witness' Omission Leads To New Vioxx Trial

Law360, New York (June 4, 2007, 12:00 AM EDT) -- In a blow to Merck & Co., a federal judge has granted one of the Vioxx plaintiffs a new trial after ruling that a key witness for the pharmaceutical giant misrepresented himself during proceedings over the controversial arthritis drug.

On Thursday, U.S. District Judge Elden Fallon breathed new life into the suit brought by Evelyn Irvin Plunkett in the wake of her husband's death from a heart attack allegedly triggered by his use of Vioxx.

“Due to a misrepresentation by one of Merck's primary witnesses that...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.